Entries |
Document | Title | Date |
20080213216 | Methods of stimulating phagocytosis - The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods. | 09-04-2008 |
20080219950 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. | 09-11-2008 |
20080219951 | Stabilization of Biologically Active Proteins With Mixtures of Polysaccharides and Amino Acid Based Compounds - The invention provides heat stable aqueous solutions or gels comprising a biologically active protein and a stabilizing effective amount of a mixture of a polysaccharide and an amino acid based compound. The invention also discloses stabilized solutions or gels suitable for use in an implantable drug delivery device at body temperature, and a device containing the stabilized solution or gels. | 09-11-2008 |
20080226596 | Therapeutic compositions and methods useful in treating hepatitis - The invention encompasses therapeutic compositions containing a pentavalent antimonial composition. The pentavalent antimonial can be sodium stibogluconate and pentamidine and biological equivalents of said compounds. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The therapeutic composition enhances cytokine activity. The therapeutic composition may include a cytokine, such as interferon α, interferon β, interferon γ, or granulocyte/macrophage colony stimulating factor. The composition may also include a second agent for treating hepatitis. | 09-18-2008 |
20080267915 | Hcv Ns3-Ns4a Protease Inhibition - The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. | 10-30-2008 |
20080292585 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom - Azonafide derivatives are obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of Cancer. | 11-27-2008 |
20080305081 | Novel aminopyrimidine derivatives as PLK1 inhibitors - The present invention relates to a compound represented by Formula [I]: | 12-11-2008 |
20080311078 | Self-Buffering Protein Formulations - The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects. | 12-18-2008 |
20090004139 | INTERFERON-BETA AND/OR LAMBDA FOR USE IN TREATING RHINOVIRUS INFECTION IN THE ELDERLY - Use of interferon-beta (IFN-β) and/or IFN-λ for treating rhinovirus (RV) infection in elderly people, particularly elderly people who are, or have been long-term smokers, especially those who have a clinical history of recurrent RV infections, and may have other medical conditions, such as cardiac or circulation problems, and who are liable to suffer severe complications/high mortality from poor innate ability to fight such a viral infection. | 01-01-2009 |
20090004140 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES - The present invention discloses compounds of Formulae (I) and (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 01-01-2009 |
20090010884 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION - The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents. | 01-08-2009 |
20090016990 | Antimicrobial Compositions - The present invention relates in part to a composition comprising a compound of Formula I or Formula II and at least one other antimicrobial agent. The invention also relates in part to a pharmaceutical composition comprising the composition of claim | 01-15-2009 |
20090022688 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds of formula I: | 01-22-2009 |
20090022689 | C4-SPIRO-PYRROLIDINE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 01-22-2009 |
20090035270 | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF alpha - The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone. | 02-05-2009 |
20090047246 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 02-19-2009 |
20090047247 | Pyrrolidine Derivatives - The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-19-2009 |
20090053175 | SUBSTITUTE PYRROLIDINE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-26-2009 |
20090060872 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS V - Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas V, V′, I″, II″, or Va, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 03-05-2009 |
20090068142 | COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION AND SARS - The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection. | 03-12-2009 |
20090074718 | Avian derived erythropoietin - Erythropoietin obtained from eggs laid by transgenic avians having avian N-linked and O-linked glycosylation patterns. | 03-19-2009 |
20090074719 | Peptides, Peptidomimetics and Small Molecule Inhibitors of the Epstein-Barr Virus Mediated Fusion and Entry Process - Disclosed are compositions and methods for modulating Epstein-Barr virus (EBV) infection in a patient. The compositions may include peptides or peptidomimetics that are related to gp42 and function to inhibit EBV-mediated membrane fusion. | 03-19-2009 |
20090081161 | Treatment of neoplasms with viruses - The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy. | 03-26-2009 |
20090087409 | Viral Polymerase Inhibitors - An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: | 04-02-2009 |
20090092582 | Compositions and methods for modifying properties of biologically active polypeptides - The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications. | 04-09-2009 |
20090123420 | Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase - The present invention provides improved treatment methods by the administration of the non-physiologic D-isomer of an IDO inhibitor. | 05-14-2009 |
20090123421 | ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS - This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-a and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-a/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity. | 05-14-2009 |
20090123422 | Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-y - A method of treating idiophathic pulmonary fibrosis (IPF), comprising administering aerosolized interferon-γ in a therapeutically effective amount to achieve improved or ameliorated symptoms of IPF. | 05-14-2009 |
20090136449 | Tetracyclic Indole Derivatives as Antiviral Agents - The present invention relates to tetracyclic indole derivatives of formula (I); wherein Ar, D | 05-28-2009 |
20090142300 | Compositions and methods related to toll-like receptor-3 - The invention relates to compositions and methods related to Toll-like receptor (TLR) polypeptides. In some embodiments, the invention relates to managing TLR3 related diseases. In further embodiments, the invention relates to methods of preventing and treating inflammation. In some embodiments, the invention relates to antagonists of TLR3, to amino acid sequences that act as dominant negative molecules, and to nucleic acid sequences that encode said amino acid sequences. In additional embodiments, the invention relates to the manipulation of biological materials to evaluate TLR3 activity. | 06-04-2009 |
20090142301 | NOVEL PHARMACEUTICAL COMPOSITION OF INTERFERON GAMMA OR PIRFENIDONE WITH MOLECULAR DIAGNOSTICS FOR THE IMPROVED TREATMENT OF INTERSTITIAL LUNG DISEASES - The present invention relates to a novel pharmaceutical composition of compounds having the biological activity of interferon gamma (IFN-γ) or pirfenidone in combination with a diagnostic array of candidate polynucleotides for the improved treatment of all forms of interstitial lung disease, in particular of idiopathic pulmonary fibrosis (IPF). | 06-04-2009 |
20090148407 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 06-11-2009 |
20090155208 | Methods and agents for modulating an immune response - This invention is directed to the targeting of proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule and methods of use thereof. Nucleic acids, vectors comprising the same, and compositions for targeting proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule are disclosed as are methods of use thereof for stimulating or enhancing immune responses in a subject. | 06-18-2009 |
20090155209 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 06-18-2009 |
20090162319 | REVERSE TRANSCRIPTASE INHIBITORS - Described herein are novel enzyme inhibitors. In some embodiments, the enzyme inhibitors are reverse transcriptase inhibitors, particularly HIV reverse transcriptase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV reverse transcriptase as a method of treating or preventing HIV, AIDS or related disorders. | 06-25-2009 |
20090175821 | Modified therapeutic peptides with extended half-lives in vivo - A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity. | 07-09-2009 |
20090196853 | METHOD OF TREATING HEPATITIS VIRUS INFECTION WITH A MULTIPHASIC INTERFERON DELIVERY PROFILE - The present invention provides methods of treating hepatitis virus infection. The methods generally involve administering a composition comprising an antiviral agent in a dosing regimen that achieves a multiphasic serum concentration profile of the antiviral agent. The dosing regimen includes dosing events that are less frequent than with currently available hepatitis therapies. The multiphasic antiviral agent serum concentration profile that is achieved using the methods of the invention effects an initial rapid drop in viral titer, followed by a further decrease in viral titer over time, to achieve a sustained viral response. | 08-06-2009 |
20090208451 | HALOGEN PHOSPHONATE MONOESTERS - The present invention relates to detection, immobilization, and production of proteolytic antibodies using halogen phosphonate monoester probes, immobilizing reagents, and antigen conjugates. | 08-20-2009 |
20090208452 | Inhibitor of Endogenous Human Interferon-Gamma - The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ inactivated by physical or chemical methods. | 08-20-2009 |
20090208453 | High pressure treatment of aggregated interferons - High pressure to treat aggregated interferons, particularly recombinant human interferon-β, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-β is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-β more amenable to high pressure treatment. It has been found that refolding yields of high pressure treatment can be significantly improved by use of a combination of strategies, including, or example a pre-treatment of the IFN-β that involves solubilizing and then precipitating the protein. This pre-treatment is particularly effective with respect to recombinant IFN-β inclusion bodies recovered from host cells such as | 08-20-2009 |
20090220456 | USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE - This invention provides a method for preventing or treating Severe Acute Respiratory Syndrome in a subject comprising administering to the subject an effective amount of recombinant super-compound interferon or a functional equivalent thereof. This invention provides a method for inhibiting the causative agent of Severe Acute Respiratory Syndrome comprising contacting the agent with an effective amount of super-compound interferon or its equivalent. | 09-03-2009 |
20090246174 | TREATMENT FOR CUTANEOUS T CELL LYMPHOMA - The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon. | 10-01-2009 |
20090257979 | Novel Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 10-15-2009 |
20090257980 | ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES - The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-λ for the same purpose. | 10-15-2009 |
20090263354 | Compositions and siRNAs for inhibiting C/EBPbeta - The invention relates to C/EBPβ and modulation of cell resistance or sensitivity to triggers of cell death. More particular, it provides pharmaceutical compositions and siRNAs for inhibiting C/EBPβ thus decreasing resistance or enhancing sensitivity of cancer cells to a cancer therapy. | 10-22-2009 |
20090269305 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 10-29-2009 |
20090274656 | HEPATITIS C VIRUS INHIBITORS - Hepatitis C virus inhibitors are disclosed having the general formula: | 11-05-2009 |
20090291062 | PROTEIN FORMULATIONS AND METHODS OF MAKING SAME - The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality. | 11-26-2009 |
20090297475 | CYSTEINE DIOXYGENASE POLYMORPHISMS - The invention relates to the detection and identification of polymorphisms in cysteine dioxygenase (CDO) for the use of that diagnosis to identify a propensity in a patient towards rheumatoid arthritis and/or to have side effects with a number of drugs, to nucleic acid and isolated proteins encoding the polymorphisms, to assays for CDO activity and for the identification of compounds affecting CDO activity, and additionally to use of interferon-γ optionally in combination with different compounds, to treat rheumatoid arthritis. | 12-03-2009 |
20090297476 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 12-03-2009 |
20090304628 | STABILIZED PHARMACEUTICAL FORMULATIONS THAT CONTAIN THE INTERFERONS GAMMA AND ALPHA IN SYNERGISTIC PROPORTIONS - The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs. | 12-10-2009 |
20090324544 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 12-31-2009 |
20100003217 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections - Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 01-07-2010 |
20100021427 | Use of Antiviral Peptides For Treatment of Infections Caused by Drug-Resistant HIV - The present invention provides methods of treating drug-resistant HIV infections especially of HIV strains that are resistant to infusion inhibitors, such as T20. | 01-28-2010 |
20100040576 | Modified Oligonucleotides For The Treatment Of Hepatitis C Infection - The invention relates to compositions and methods related to the treatment of viral infection. In some embodiments, the invention relates to the treatment of hepatitis C viral infection. In further embodiments, the invention relates to methods of administering oligonucleotide compositions for treating viral infections. In still further embodiments, the invention relates to the administration of antiviral agents, corticosteroids and immunomodulatory agents. In additional embodiments, the invention relates to the manipulation of immunostimulatory motifs within the oligonucleotides. | 02-18-2010 |
20100074863 | ANTI-INFECTIVE PYRROLIDINE DERIVATIVES AND ANALOGS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-25-2010 |
20100098660 | Method of treating tuberculosis with interferons - A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient suffering from tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided. | 04-22-2010 |
20100111902 | COMPOSITION FOR TRANSMUCOSAL DELIVERY OF POLYPEPTIDES - The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide. | 05-06-2010 |
20100119479 | THERAPEUTIC ANTIVIRAL PEPTIDES - Disclosed herein are compounds represented by a formula: | 05-13-2010 |
20100124544 | CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE - The present invention relates to the crystalline forms of 2-allyl-1-[6-(I-hydroxy-1 methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one or a salt thereof, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor. | 05-20-2010 |
20100135960 | ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-03-2010 |
20100150867 | USE OF ALPHA-GLUCOSIDASE INHIBITORS TO TREAT ALPHAVIRUS INFECTIONS - The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent. | 06-17-2010 |
20100158865 | Inhibitor of endogenous human interferon-gamma - The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ, where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ, inactivated by physical or chemical methods. | 06-24-2010 |
20100183551 | Macrocyclic Compounds As Antiviral Agents - A class of macrocyclic compounds of formula (I), wherein R | 07-22-2010 |
20100209391 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments also provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 08-19-2010 |
20100221214 | LINKED DIBENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-02-2010 |
20100221215 | LINKED DIBENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-02-2010 |
20100221216 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-02-2010 |
20100221217 | THERAPEUTIC COMPOSITION - Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. | 09-02-2010 |
20100226881 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY - Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs. | 09-09-2010 |
20100226882 | LINKED DIIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-09-2010 |
20100226883 | LINKED DIIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-09-2010 |
20100226884 | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) - The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer. | 09-09-2010 |
20100233122 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-16-2010 |
20100233123 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS - Provided herein are phosphothiophene and phosphothiazole compounds, for example, of any of Formulae I, IA, IIA, IIIA, IVA, VA, VIA, VIIA, IB, IIB, IIIB, IVB, VB, VIIB and VIIB disclosed herein, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host infected with HCV. | 09-16-2010 |
20100254942 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS - The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity. | 10-07-2010 |
20100260715 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-14-2010 |
20100266541 | METHODS AND AGENTS FOR MODULATING AN IMMUNE RESPONSE - This invention is directed to the targeting of proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule and methods of use thereof. Nucleic acids, vectors comprising the same, and compositions for targeting proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule are disclosed as are methods of use thereof for stimulating or enhancing immune responses in a subject. | 10-21-2010 |
20100266542 | RECEPTOR COUPLING AGENTS AND THERAPEUTIC USES THEREOF - Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed. | 10-21-2010 |
20100266543 | LINKED DIBENZIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-21-2010 |
20100272681 | Inhibitors of Serine Proteases - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. | 10-28-2010 |
20100272682 | METHOD FOR IMPROVING PHARMACOKINETICS - The object of the present invention is to elevate the blood levels of a compound of formula I by co-administration with a cytochrome P450 inhibitor. | 10-28-2010 |
20100284969 | Methods and Compositions for Delivery of Medicaments to the Lungs - The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs. | 11-11-2010 |
20100310511 | DETERMINING DISEASE OR IMMUNE SYSTEM FEATURES BASED ON ANALYSIS OF IMMUNE SYSTEM CHARACTERISTICS - Methods for analyzing one or more elements, markers, ligands or other characteristics of the immune system of a body (e.g., of a human or other animal), and based on the analysis, determine a location of disease, identify immune system failure, and/or determine treatments based on disease location or immune system failure. All or a part of the immune system process may be analyzed to identify specific features of the immune system, e.g., which may indicate that the disease will evade the immune system and produce a negative outcome. Therapy may be employed to correct immune system failure rather than addressing the disease directly. | 12-09-2010 |
20100316607 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 12-16-2010 |
20100330034 | USE OF BISPECIFIC ANTIBODIES TO REGULATE IMMUNE RESPONSES - The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor. | 12-30-2010 |
20110002884 | THERAPEUTIC COMPOUNDS - A class of macrocyclic compounds of formula (I), wherein R | 01-06-2011 |
20110008288 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 01-13-2011 |
20110033419 | Methods and Compositions for Treating Cancer - The invention relates to a method of treating cancer, comprising administering to a subject in need thereof an effective amount of a HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10. The invention further relates to pharmaceutical compositions comprising HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10. | 02-10-2011 |
20110038834 | NOVEL AVIAN CYTOKINES AND GENETIC SEQUENCES ENCODING SAME - The present invention relates generally to novel recombinant polypeptides having avian cytokine properties and to genetic sequences encoding same. More particularly, the present invention is directed to recombinant avian Type III interferon polypeptides, and genetic sequences encoding same, together with cellular expression systems and uses for same. Even more particularly, the present invention is directed to avian interferon-λ (IFN-λ) and functional derivatives, homologues and fragments thereof and to methods of use thereof. The molecules and cells of the present invention are useful in a wide range of applications including, but not limited to, providing a means for the treatment and prophylaxis of disease conditions, in particular avian disease conditions, or for use as an immune response modulator. Also provided are diagnostic means for screening for immune response and screening means for identifying modulators of IFN-λ protein or nucleic acid functionality. | 02-17-2011 |
20110059044 | Method of treating pulmonary disease with interferons - A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided. | 03-10-2011 |
20110064697 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
20110064698 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-17-2011 |
20110070196 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-24-2011 |
20110070197 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-24-2011 |
20110081315 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, and XII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 04-07-2011 |
20110086006 | HCV NS3-NS4 Protease Resistance Mutants - The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment. | 04-14-2011 |
20110091421 | Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases - The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorder involving targeting microRNAs are also disclosed. | 04-21-2011 |
20110104115 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds. | 05-05-2011 |
20110110890 | Novel Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formula I and compound 105S, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 05-12-2011 |
20110123495 | DERIVATIVES OF PYRIDONE AND USE THEREOF - The present invention provides N-substituted-2(1H) pyridones or the pharmaceutical acceptable salts thereof, and the pharmaceutical preparations containing the compounds. The compounds of the present invention can be used to treat various fibrotic diseases effectively, e.g., hepatic fibrosis. | 05-26-2011 |
20110129444 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 06-02-2011 |
20110135601 | BICYCLOANILINE DERIVATIVE - The invention relates to a compound of a general formula (I): | 06-09-2011 |
20110135602 | SUPPERSSOR OF THE ENDOGENOUS INTERFERON-GAMMA - The invention relates to suppressor of the endogenous human interferon-gamma (hlFN-γ) applicable in treatment of diseases associated with impaired activity of endogenous hlFN-γ, especially autoimmune diseases and for prevention of graft arteriosclerosis and rejection of organs in allograft transplanted patients. It is based on inactive analogues of the hlFN-γ with pre-served affinity to the hlFN-γ receptor, genetically modified in the domain responsible for triggering the signal transduction pathway. | 06-09-2011 |
20110142799 | MODULATION OF NEURODEGENERATIVE DISEASE BY MODULATING XBP-1 ACTIVITY - The invention provides methods for treating and preventing a neurodegenerative disease associated with aberrant protein aggregation by modulating the expression and/or activity of XBP-1, IRE-1 alpha, and/or EDEM. The present invention also pertains to methods for identifying compounds that modulate the expression and/or activity of XBP-1, 1RE-1 alpha, and/or EDEM. The present invention further provides methods for determining whether a subject is at risk of developing or has developed a neurodegenerative disease associated with aberrant protein aggregation. | 06-16-2011 |
20110142800 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS - This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, methods for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same. | 06-16-2011 |
20110150832 | FURIN-KNOCKDOWN BI-FUNCTIONAL RNA - Compositions and methods to attenuate the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. | 06-23-2011 |
20110165121 | USE OF PEGYLATED TYPE III INTERFERONS FOR THE TREATMENT OF HEPATITIS C - Methods for treating human patients infected with the hepatitis C virus using pegylated Type III Interferons (IL-28A, IL-28B and IL-29) alone or in combination with other antiviral agents. | 07-07-2011 |
20110171175 | INHIBITORS OF SERINE PROTEASES - This invention relates to compounds of formula I: | 07-14-2011 |
20110177026 | Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections - The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent. | 07-21-2011 |
20110177027 | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha - The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone. | 07-21-2011 |
20110182856 | INHIBITORS OF SERINE PROTEASES - The present invention relates to compounds of formula (I): | 07-28-2011 |
20110182857 | Delivery of Drugs to Mucosal Surfaces - Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions. | 07-28-2011 |
20110189129 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 08-04-2011 |
20110189130 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES - The invention relates to compounds of a general formula (I): | 08-04-2011 |
20110223133 | THERAPEUTIC AGENT FOR HEMATOPOIETIC TUMORS - An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24. | 09-15-2011 |
20110236349 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection - The present invention provides methods of treating a viral infection in an individual. The methods generally involve administering to an individual an effective amount of an epidermal growth factor receptor (EGF-R) inhibitor. | 09-29-2011 |
20110243891 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE - The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar | 10-06-2011 |
20110243892 | Y-SHAPE BRANCHED HYDROPHILIC POLYMER DERIVATIVES, THEIR PREPARATION METHODS, CONJUGATES OF THE DERIVATIVES AND DRUG MOLECULES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE CONJUGATES - The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates. | 10-06-2011 |
20110250172 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-13-2011 |
20110250173 | Methods and compositions for inhibition of Treg cells - The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effector T lymphocytes. The invention includes administering a therapeutic composition that promotes a Th1 environment in the patient while decreasing the immunosuppressive activity of Treg cells that can lead to disease antigen tolerance and immunoavoidance of the disease antigens by the patient. The therapeutic composition includes allogeneic emTh-1 cells. The therapeutic composition can also include disease antigens such as the chaperone-rich cell lysate of the disease antigen. | 10-13-2011 |
20110250174 | STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES - The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond. | 10-13-2011 |
20110262398 | CARDIAC TREATMENT USING ANTI-FIBROTIC AGENTS - Disclosed herein are reagents and methods for detecting and treating age-related diastolic dysfunction in an animal or a human. | 10-27-2011 |
20110274653 | DENDRITIC CELL IMMUNORECEPTORS (DCIR)-MEDIATED CROSSPRIMING OF HUMAN CD8+ T CELLS - Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8+ T cell immunity by all human DC subsets including ex vivo generated DCs, skin-isolated Langerhans cells and blood mDCs and pDCs. Enhanced specific CD8+ T cell responses were observed when antigens like, FluMP, MART-1, viral (HIV gag), etc. were delivered to the DCs via DCIR, compared to those induced by a free antigen, or antigen conjugated to a control mAb or delivered via DC-SIGN, another lectin receptor. Addition of Toll-like receptor (TLR) 7/8-agonist enhanced DCIR-mediated crosspresentation as well as crosspriming. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8+ T cell immunity. | 11-10-2011 |
20110274654 | TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE - Provided herein are triazole FASN inhibitors of the formula (I): | 11-10-2011 |
20110274655 | TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE - Provided herein are tetrazolone FASN inhibitors of the formula (I): | 11-10-2011 |
20110274656 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS C, COMPRISING THE ROOTS EXTRACT OF PLATYCODON GRANDIFLORUM OR PLATYCODON GRANDIFLORUM SAPONIN COMPONENTS - The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of | 11-10-2011 |
20110280829 | Low Molecular Weight Sulphated Polysaccharides as Candidates for Anti-Angiogenic Therapy - Low molecular weight sulphated L-fucose polysaccharide fraction having a molecular weight ranging from 11 to 30 kDa when measured with TEST A, a sulphate content ranging from 10 and 50% w/w relative to the total weight of the fraction, a fucosis content ranging from 30 and 70% w/w relative to the total weight of the fraction, and a polydispersity index ranging from 1 and 2, wherein the fraction is obtainable by free radical depolymerisation of a crude fucan of vegetal origin; process for manufacturing same; pharmaceutical composition and medicament containing same and their use for inhibiting neovascularisation. | 11-17-2011 |
20110286966 | Inhibitor of Endogenous Human Interferon-gamma - Modified endogenous human interferon-gamma (hIFN-γ), biologically inactive but preserving binding affinity to the hIFN-γ receptor, has applicability in the treatment of autoimmune diseases, especially multiple sclerosis. | 11-24-2011 |
20110286967 | LONG-ACTING INTERFERONS AND DERIVATIVES THEREOF AND METHODS THEREOF - A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed. | 11-24-2011 |
20110300104 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 12-08-2011 |
20110305667 | USE OF A DEAD-BOX RNA HELICASE FOR INDUCING CYTOKINE PRODUCTION - The invention relates to the use of a DEAD-box RNA helicase from a yeast, a mammal, | 12-15-2011 |
20110305668 | METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE - Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space. | 12-15-2011 |
20120009149 | Tetrameric Cytokines with Improved Biological Activity - The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b. | 01-12-2012 |
20120014914 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES - The present invention relates to compounds of formula I: | 01-19-2012 |
20120034186 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER - Protein tyrosine phosphatase (PTP) Shp2 is a non-receptor PTP that involved in cell signaling and regulation of cell proliferation, differentiation, and migration. Shp2 mediates activation of kinases that are involved in the pathogenesis of human carcinoma. A high throughput screen identified compounds that inhibit the PTP Shp2. Several compounds were identified that selectively inhibit Shp2 over Shp1 with low to sub-micromolar activity. Also disclosed are methods of inhibiting a protein tyrosine phosphatase in a cell and treating cancer through selective inhibition of Shp2. | 02-09-2012 |
20120039848 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 02-16-2012 |
20120045415 | TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN - The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs. | 02-23-2012 |
20120058081 | Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-λ | 03-08-2012 |
20120058082 | METHODS AND COMPOSITIONS FOR TREATMENT - The invention provides methods for improving the efficacy and reducing side effects of anti-CD52 antibody treatment. The methods can be used to treat patients who are in need of immunoregulation such as lymphocyte depletion and patients who have cancer. Also included are compositions useful for these methods. | 03-08-2012 |
20120070414 | Controlling disease vectors from insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi - The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect and arthropod attractants and/or pathogens and can be employed to limit the zoonotic and plant diseases they transmit. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material and extracts can be made thereof. More than one fungus and substrate can be used in combination with one or more antimicrobial, antiprotozoal, antiviral, or genetically modified agents that result in reduced spread of contagions and lessens the damage they inflict on animals and plants. | 03-22-2012 |
20120076755 | Hepatitis C Virus Inhibitors - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-29-2012 |
20120076756 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 03-29-2012 |
20120076757 | COMPOSITION FOR TRANSMUCOSAL DELIVERY OF POLYPEPTIDES - The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide. | 03-29-2012 |
20120114603 | IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES - A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions. | 05-10-2012 |
20120114604 | Combinations for HCV Treatment - The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs. | 05-10-2012 |
20120148532 | Method of treating pulmonary disease with interferons - A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided. | 06-14-2012 |
20120164104 | Composition and Methods of Treating Viral Infections and Viral Induced Tumors - The present invention provides methods of treating viral induced tumor or viral infections, including administering a compound described in the invention in a therapeutically effective amount. According to some aspect of the present invention, the methods may further comprise at least one immunosuppressant agent to treat viral infection and/or viral induced tumor to a subject in need of immunosuppressant agents. | 06-28-2012 |
20120183499 | Method of treating pulmonary disease with interferons - A method of treating a pulmonary disease such as, for instance idiopathic pulmonary fibrosis (IPF), mixed connective tissue disease and asthma, comprising administering an aerosolized interferon such as interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) alone or in combination with other therapeutic agents are provided. | 07-19-2012 |
20120213734 | Method for Cancer Therapy Based on a Co-Administration of a Parvovirus and a Cytokine - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-γ, and the use of said composition for treatment of cancer, e.g., a brain tumor. | 08-23-2012 |
20120219523 | Method of treating tuberculosis with interferons - A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient suffering from tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided. | 08-30-2012 |
20120225032 | Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo - The present invention concerns methods and compositions for PEGylated complexes of defined stoichiometry and structure. Preferably, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and a PEG moiety to an AD sequence, allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. Alternatively, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases. | 09-06-2012 |
20120251493 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 10-04-2012 |
20120263680 | Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix Deposition - The described invention provides compositions and methods for preventing or treating a disease, condition, or pathologic process characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject. The method includes administering a therapeutic amount of a pharmaceutical composition comprising a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier. | 10-18-2012 |
20130064790 | PEPTIDES WITH THE CAPACITY TO BIND TO INTERLEUKIN-10 (IL-10) - The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions. | 03-14-2013 |
20130064791 | Interferon Analogs - The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor. | 03-14-2013 |
20130101553 | INDUCING INACTIVATION OF FIBROGENIC MYOFIBROBLASTS - Provided are methods of treating fibrotic conditions in a subject and diagnostic methods for determining fibrosis and appropriate treatments for the fibrosis by the identification of specific subsets of fibrogenic myofibroblasts. | 04-25-2013 |
20130129678 | CO-ADMINISTRATION OF A PARVOVIRUS AND A CYTOKINE FOR THERAPY OF PANCREATIC CANCER - The application relates to a combination of a parvovirus and a cytokine, preferably IFNγ, for use in treating pancreatic cancer (PDAC), in particular a terminal stage of this disease. | 05-23-2013 |
20130156734 | Compositions and Methods for Treating Friedreich's Ataxia with Interferon Gamma - Described herein are compositions and methods for treating Friedreich's Ataxia (FRDA) with interferon gamma. In some aspects, methods for increasing expression of frataxin in cells and for treating Friedreich's Ataxia are provided. In some additional aspects, methods increasing aconitase activity in cells are provided. | 06-20-2013 |
20130171104 | SYNERGISTIC ACTIVITY OF MODULATORS OF THE NO METABOLISM AND OF NADPH OXIDASE IN THE SENSITIZATION OF TUMOR CELLS - What is disclosed is pharmaceutical compositions which contain a pharmaceutically active amount of at least one active substance which increases the available NO concentration in the cell, together with at least one active substance which stimulates the NADPH oxidase. | 07-04-2013 |
20130177531 | Inhibitors of Serine Proteases - This invention relates to compounds of formula I: | 07-11-2013 |
20130183269 | Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein. | 07-18-2013 |
20130243727 | TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE - Provided herein are triazole FASN inhibitors of the formula (I): | 09-19-2013 |
20130251676 | ANTICANCER FUSION PROTEIN - A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases. | 09-26-2013 |
20130295049 | LINKED DIBENZIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-07-2013 |
20130309198 | COMPOSITION COMPRISING AT LEAST TO COMPOUNDS WHICH INDUCES INDOLAMINE 2,3 - DIOXYGENASE (IDO), FOR THE TREATMENT OF AN AUTOIMMUNE DISORDER OR SUFFERING FROM IMMUNE REJECTION OF ORGANS - A composition and method for using a composition, the composition having at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels. | 11-21-2013 |
20140010784 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. | 01-09-2014 |
20140050700 | EX-VIVO TREATMENT OF PERIPHERAL BLOOD LEUKOCYTES WITH IFN-Lambda - The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-λ | 02-20-2014 |
20140056847 | INHIBITORS OF SERINE PROTEASES - This invention relates to compounds of formula I: | 02-27-2014 |
20140065102 | METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS - It is disclosed a method for the treatment of HBV infection or HBV/HDV co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function. | 03-06-2014 |
20140079667 | TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE - Provided herein are tetrazolone FASN inhibitors of the formula (I): | 03-20-2014 |
20140086869 | METHODS AND COMPOSITIONS FOR TREATING TUMORS USING MYELOID DERIVED SUPPRESSOR CELLS - Compositions and methods for diagnosing and treating tumors using myeloid derived suppressor cells (MDSCs) are provided. More particularly, the compositions contain labeled MDSCs or MDSCs in combination with oncolytic viruses, nano-particles or other anti-tumor agents. | 03-27-2014 |
20140127158 | COMBINATION THERAPY FOR HEPATITIS C VIRUS INFECTION - A method of treating hepatitis C virus infection, comprising administering to a subject in need thereof (a) an effective amount of at least one HCV inhibitor selected from the group consisting of an HCV NS3 inhibitor, an HCV NS5B inhibitor, ribavirin, and an IFN-α; and (b) an effective amount of an anti-HCV compound of formula (I). | 05-08-2014 |
20140147414 | COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE - Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as | 05-29-2014 |
20140154209 | POLYMORPHISMS ASSOCIATED WITH NON-RESPONSE TO A HEPATITIS C TREATMENT OR SUSCEPTIBILITY TO NON-SPONTANEOUS HEPATITIS C CLEARANCE - The present invention relates to in vitro methods of determining a susceptibility to non-response to a hepatitis C treatment or a susceptibility to non spontaneous hepatitis C clearance in a subject infected with hepatitis C. | 06-05-2014 |
20140212383 | SUPPRESSOR OF THE ENDOGENOUS INTERFERON-GAMMA - The invention relates to suppressors of endogenous human interferon-gamma (INF-γ) applicable in treatment of diseases associated with impaired activity of endogenous IFN-γ. The suppressors of the invention are useful in treating autoimmune diseases and for prevention of graft arteriosclerosis and rejection of organs in allograft transplanted patients. The invention includes inactive analogues or variants of IFN-γ having preserved affinity to the IFN-γ receptor, genetically modified in the domain responsible for triggering the signal transduction pathway. | 07-31-2014 |
20140234253 | Combination Treatments For Hepatitis C - The present invention features methods and pharmaceutical compositions for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formula (I), (II), (III), (IV), (V), or (VI) described herein or a pharmaceutically acceptable salt thereof in combination with one or more additional Hepatitis C therapeutic agents. | 08-21-2014 |
20140248237 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 09-04-2014 |
20140248238 | POLYPEPTIDE CONSTRUCTS AND USES THEREOF - The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen. | 09-04-2014 |
20140301980 | METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS USING APREMILAST - Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with a second active agent. | 10-09-2014 |
20140308243 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-16-2014 |
20140328797 | HUMAN RHINOVIRUS (HRV) ANTIBODIES - The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis. | 11-06-2014 |
20140328798 | Co-Administration of a Parvovirus and a Cytokine for Therapy of Pancreatic Cancer - The present invention relates to a combination of a parvovirus and a cytokine, preferably IFNγ, for use in treating pancreatic cancer, in particular a terminal stage of this disease. | 11-06-2014 |
20140335050 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER - The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer. | 11-13-2014 |
20140341851 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-20-2014 |
20140348788 | METHOD TO MODULATE PIGMENTATION PROCESS IN THE MELANOCYTES OF SKIN - The invention describes a method to modulate melanosome maturation process in melanocytes. Further, it describes a method to reversibly alter the process of pigmentation in the human epidermal skin. The method targets melanosome maturation and its transfer to keratinocytes, which are key processes involved in the pigmentation for its potential use in predictable and controlled regulation of pigmentation in human skin. | 11-27-2014 |
20140369962 | METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS - It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function. | 12-18-2014 |
20140369963 | METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS - It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function. | 12-18-2014 |
20150010504 | Antiviral Compounds with a Heterotricycle Moiety - Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R | 01-08-2015 |
20150010505 | Antiviral Compounds with a Dibenzooxaheterocycle Moiety - Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R-R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. (I). | 01-08-2015 |
20150023918 | LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME - Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin. | 01-22-2015 |
20150023919 | INDUCTION OF TOLERANCE IN LUNG ALLOGRAFT TRANSPLANTATION - The present disclosure relates to methods of inducing tolerance to lung allograft transplantation. These methods comprise increasing nitric oxide, increasing suppressor CD8 | 01-22-2015 |
20150023920 | NOVEL COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING CANCER METASTASIS - The invention includes a method of preventing or treating metastasis in a subject diagnosed with cancer, the method comprising determining whether at least one gene encoding one or more proteins is upregulated in a cancer tissue sample from the subject as compared to the level of expression of the at least one gene in a non-cancer control sample of the same tissue, and, if the at least one gene is upregulated in the cancer tissue sample from the subject, administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising one or more protein depleting agents. | 01-22-2015 |
20150030564 | INHIBITORY AGENT FOR BODY CAVITY FLUID ACCUMULATION - An inhibitory agent for body cavity fluid accumulation exerts a drug efficacy on body cavity fluid accumulation that is resistant to administration of diuretics, and is capable of exerting therapeutic effects even by systemic administration. The inhibitory agent for body cavity fluid accumulation includes, as an active ingredient, a covalent conjugate of interferon with polyalkylene glycol. | 01-29-2015 |
20150064134 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION - The described invention provides compositions and methods for treating asthma, a disease, condition or pathologic process whose progression is characterized by one or more of aberrant fibroblast proliferation and extracellular matrix deposition producing constriction in an airway, airway remodeling, and airway obstruction in lung tissue. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce the constriction of small airway dimensions and airway obstruction, treat airway remodeling, or a combination thereof. | 03-05-2015 |
20150079034 | COMPOSITIONS COMPRISING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF - The present invention provides recombinant | 03-19-2015 |
20150132258 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS - Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | 05-14-2015 |
20150315159 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS - Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | 11-05-2015 |
20150329873 | FURIN-KNOCKDOWN AND GM-CSF-AUGMENTED (FANG) CANCER VACCINE - Compositions and methods for cancer treatment are disclosed herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. | 11-19-2015 |
20150343024 | USE OF ACTIVE SUBSTANCE COMBINATIONS FOR INDUCING TUMOUR SENESCENCE - The present invention relates to a combination of at least two different substances, one of which activates the STAT1-signalling cascade and the other of which activates the TNFR1/CD95-signalling cascade in order to induce permanent growth arrest—i.e. senescence—in pre-malignant or malignant tumors or tumor cells. This induction of permanent growth arrest does not depend on cytotoxicity and does not primarily attempt to kill tumor cells, although this may occur. The induction serves to treat and/or prevent tumors by permanent growth arrest. The combination is used for therapeutic or preventative senescence induction in tumors, in which the STAT1- and TNFR1/CD95-signalling cascade can be activated and in which p16lnk4a is present. The invention transfers tumor cells and, contrary to many other therapies, the tumor stem cells, into permanent growth arrest. | 12-03-2015 |
20150343037 | TREATMENT OF BONE DISEASES - The invention relates generally to the field of bone diseases. More specifically, the invention relates to methods and compositions for the treatment of osteoporosis and related disorders. | 12-03-2015 |
20150366939 | SUPPRESSION OF MALIGNANT MESOTHELIOMA BY OVEREXPRESSION OR STIMULATION OF ENDOTHELIAL PROTEIN C RECEPTORS (EPCR) - The influence of TF, endothelial cell protein C receptor (EPCR) and protease activated receptor-1 (PAR1) on tumor growth of malignant pleural mesothelioma (MPM) is disclosed. MPM cells that lack or express TF, EPCR or PAR1 and a murine orthotopic model of MPM led to the discovery that intrapleural administration into nude mice of REN MPM cells expressing TF and PAR1 but lacking EPCR and PAR2 generated large pleural cavity tumors. Suppression of TF or PAR1 expression markedly reduced tumor growth. Overexpression of TF in non-aggressive MPM cells expressing EPCR and PAR1 but exhibiting minimal levels of TF failed to alter their tumorigenicity. Introduction of EPCR expression in aggressive MPM cells attenuated tumor growth whereas EPCR silencing in non-aggressive MPM cells overexpressing TF increased tumorigenicity of non-aggressive cells. Expression of EPCR by MPM cells suppresses tumor growth and treats MPM. | 12-24-2015 |
20150368651 | FURIN-KNOCKDOWN BI-FUNCTIONAL RNA - Compositions and methods to attenuate the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. | 12-24-2015 |
20160000812 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS - Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | 01-07-2016 |
20160045594 | DIRECTED IMMUNE STIMULATION - A synthetic polypeptide vaccine is employed for directed targeting of an individual's immune response to an antigen of interest. The synthetic polypeptide contains a carrier epitope specific for open conformers of an individual's MHC-I molecules in the presence of HLA-F, and also contains an effector epitope which elicits an immune response to the antigen of interest. The effect- or epitope may modulates an immune response to a tumor, pathogen, or autoantigen associated with an autoimmune disorder. The present vaccine exploits a role for the interaction between HLA-F and open conformers of MHC-I in the uptake of extracellular antigen for cross presentation. | 02-18-2016 |
20160053012 | COMPOSITIONS AND METHODS FOR PRESERVING CELLS OF THE EYE - The invention provides a method of preserving ocular cells in a patient having or at risk of developing glaucoma. In particular, microglial cell activation can be decreased, oligodendrocyte loss can be reduced, and/or the viability of retinal ganglion cells can be preserved by administering a selective TNFR2 antagonist to an individual having or at risk of developing glaucoma. | 02-25-2016 |
20160082085 | Co-Administration of a Parvovirus and a Cytokine for Therapy of Pancreatic Cancer - The present invention relates to a combination of a parvovirus and a cytokine, preferably IFN | 03-24-2016 |
20160106806 | GLA DOMAINS AS TARGETING AGENTS - The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. | 04-21-2016 |
20160115242 | ANTI-CSPG4 FUSIONS WITH INTERFERON FOR THE TREATMENT OF MALIGNANCY - In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha or to an interferon beta (IFN-β) or to a mutant interferon beta, or to an interferon gamma (IFN-γ) or to a mutant interferon gamma. | 04-28-2016 |
20160136234 | Compositions and Methods for Preventing or Treating Diseases, Conditions, or Processes Characterized by Aberrant Fibroblast Proliferation and Extracellular Matrix Deposition - The described invention provides compositions and methods for reducing progression of a fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the progression of the fibrosis being characterized by aberrant fibroblast proliferation and extracellular matrix deposition in the tissue. The method includes administering a therapeutic amount of a pharmaceutical composition containing a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce progression of the fibrosis, to treat remodeling of the tissue, or a combination thereof. | 05-19-2016 |
20160151375 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | 06-02-2016 |
20160158214 | HEPATITIS B ANTIVIRAL AGENTS - Provided herein are compounds useful for the treatment of HBV infection in man. | 06-09-2016 |
20160169890 | TRACKING DONOR-REACTIVE TCR AS A BIOMARKER IN TRANSPLANTATION | 06-16-2016 |
20160184446 | METHOD OF INHIBITING BODY CAVITY FLUID ACCUMULATION - A method of inhibiting accumulation of body cavity fluid in a subject in need thereof includes administering a covalent conjugate of interferon with polyalkylene glycol to the subject wherein the polyalkylene glycol is polyethylene glycol, the interferon is type I interferon or interferon-λ, and the type I interferon is interferon-α or interferon-β. | 06-30-2016 |
20160185748 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT - The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention. | 06-30-2016 |
20160193219 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SALTS | 07-07-2016 |
20160250142 | INHALED AEROSOLIZED IMMUNO-CHEMOTHERAPY FOR THE TREATEMENT OF MDR TB | 09-01-2016 |
20180021401 | COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE AND BACTERIAL INFECTION | 01-25-2018 |